A purified cyclohexanol of the present invention has a methylcyclopentanol concentration of 10 to 1000 ppm by weight and a cyclohexylcyclohexene isomer concentration of 15 to 500 ppm by weight. A method for producing cyclohexanol of the present invention comprises: Step 1 of producing a solution (I) containing cyclohexanol, methylcyclopentanol, and water by a hydration reaction of cyclohexene; Step 2 of separating the solution (I) into a water phase and an oil phase; Step 3 of obtaining a partially purified cyclohexanol containing methylcyclopentanol from the oil phase; and Step 4 of separating and removing methylcyclopentanol in the partially purified cyclohexanol so as to obtain a purified cyclohexanol having a methylcyclopentanol concentration of 10 to 1000 ppm by weight and a cyclohexylcyclohexene isomer concentration of 15 to 500 ppm by weight.

A purified cyclohexanol of the present invention has a methylcyclopentanol concentration of 10 to 1000 ppm by weight and a cyclohexylcyclohexene isomer concentration of 15 to 500 ppm by weight. A method for producing cyclohexanol of the present invention comprises: Step 1 of producing a solution (I) containing cyclohexanol, methylcyclopentanol, and water by a hydration reaction of cyclohexene; Step 2 of separating the solution (I) into a water phase and an oil phase; Step 3 of obtaining a partially purified cyclohexanol containing methylcyclopentanol from the oil phase; and Step 4 of separating and removing methylcyclopentanol in the partially purified cyclohexanol so as to obtain a purified cyclohexanol having a methylcyclopentanol concentration of 10 to 1000 ppm by weight and a cyclohexylcyclohexene isomer concentration of 15 to 500 ppm by weight.

The present invention relates to a method for preparing N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide, which is a novel benzamide derivative as a 5-HT4 receptor agonist, or a pharmaceutically acceptable salt thereof; to a novel intermediate capable of being used in the preparation of the compounds; and to a method for preparing the same. The preparation methods of the present invention can be useful for mass production since a low-priced reagent and intermediate are used and the number of reaction processes is decreased, thereby saving preparation costs and improving the yield.

The present invention relates to a method for preparing N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide, which is a novel benzamide derivative as a 5-HT4 receptor agonist, or a pharmaceutically acceptable salt thereof; to a novel intermediate capable of being used in the preparation of the compounds; and to a method for preparing the same. The preparation methods of the present invention can be useful for mass production since a low-priced reagent and intermediate are used and the number of reaction processes is decreased, thereby saving preparation costs and improving the yield.

BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.

BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.

This invention relates to the field of plastic waste decomposition. More specifically, the invention comprises products obtained from the decomposition of plastic waste.

This invention relates to the field of plastic waste decomposition. More specifically, the invention comprises products obtained from the decomposition of plastic waste.

Crystalline forms of upadacitinib and processes for preparation thereof are disclosed. The present disclosure also relates to pharmaceutical compositions containing the upadacitinib crystalline forms, use of the upadacitinib crystalline forms for preparing JAK1 inhibitor drugs, and use of the upadacitinib crystalline forms for preparing drugs treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis. The crystalline forms of upadacitinib provided by the present disclosure have one or more improved properties compared with prior arts and have significant values for future drug optimization and development.

##STR00001##

Disclosed herein are a crystalline or amorphous form of a Bcl-2/Bcl-xL inhibitor compound or a salt thereof, and a preparation method and application thereof.